Navigation MenuRealWire Limited

Delivering Relevance, Releasing Influence

Tweet Facebook LinkedIn
Press Release

PAREXEL Wins Best Technological Development In Clinical Trial Award At The 11th Annual Scrip Awards


LONDON, December 18, 2015 - PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, announced today that its Country Allocation Technology won the Best Technological Development in Clinical Trials Award at the 2015 Scrip Awards. The award recognises the importance of PAREXEL’s Country Allocation Technology across the drug development value chain.

Country selection, patient recruitment, and patient enrollment are among the most fundamental needs in drug development. Delays in one of these areas can cost a biopharmaceutical company time and money in getting a new drug to a patient in need. To address this challenge, PAREXEL developed its Country Allocation Technology, providing feasibility teams a data-driven tool for country selection.

“This award honors PAREXEL’s long history of innovation in clinical trial technology,” said Paul Evans, Vice President, Site Strategy & Start-Up, PAREXEL. “Our Country Allocation Technology provides a data-driven approach to country selection for a clinical trial. By looking at a variety of data, we provide clients with a clear ranking of countries for their specific trial based on medical, clinical, operational, regulatory, and financial criteria.”

PAREXEL was one of six finalists in the Best Technological Development in Clinical Trials category, which focused on identifying the product that represents the best advance in supporting clinical trial management. In selecting PAREXEL as the winner, the judges explained: “The cost savings are massive. If we can get the feasibility right, we can progress studies more efficiently.”

“At PAREXEL, we believe the world would be a healthier place if the journey between science and new treatments were simpler. We innovate continuously to provide technology services that empower our clients to make data-driven business decisions, helping to reduce risk and to speed time to market,” added David Kiger, Vice President, Product Strategy, PAREXEL Informatics.

About the Scrip Awards Best Technological Development in Clinical Trials Award
The Best Technological Development in Clinical Trials Award recognizes the vital importance of using the most sophisticated platforms to catalyze and optimize data gathering during clinical trials. It celebrates the advances in software and applications that are playing a pivotal role in the trial process, from patient recruitment and compliance, to managing and mining outcomes or safety data.

About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of expertise-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 80 locations in 51 countries around the world, and had approximately 18,620 employees in the first quarter. For more information about PAREXEL International visit

PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners.

This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.

# # #

Cristi Barnett, PAREXEL International
Tel.: +1 781-434-4019

Charlotte Bass, onechocolate Communications
Tel.: +44 (0) 20 7437 0227